Phreesia, Inc. (0A23.L)
USD 25.52
(2.82%)
USD 25.52
(2.82%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 2.04 Million USD | -33.34% |
| 2023 | 3.07 Million USD | -64.66% |
| 2022 | 8.69 Million USD | 3.93% |
| 2021 | 8.37 Million USD | -61.14% |
| 2020 | 21.54 Million USD | -28.96% |
| 2019 | 30.31 Million USD | 50.8% |
| 2018 | 20.1 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q4 | 2.04 Million USD | -70.81% |
| 2024 FY | 2.04 Million USD | -33.34% |
| 2024 Q1 | 6.94 Million USD | 154.9% |
| 2024 Q2 | 8.27 Million USD | 19.08% |
| 2024 Q3 | 7.01 Million USD | -15.14% |
| 2023 Q1 | 6.94 Million USD | -20.15% |
| 2023 Q4 | 3.07 Million USD | -27.28% |
| 2023 FY | 3.07 Million USD | -64.66% |
| 2023 Q3 | 4.22 Million USD | -24.06% |
| 2023 Q2 | 5.56 Million USD | -19.87% |
| 2022 Q2 | 7.01 Million USD | -3.08% |
| 2022 Q4 | 8.69 Million USD | 39.16% |
| 2022 Q3 | 6.25 Million USD | -10.83% |
| 2022 Q1 | 7.23 Million USD | -13.58% |
| 2022 FY | 8.69 Million USD | 3.93% |
| 2021 FY | 8.37 Million USD | -61.14% |
| 2021 Q1 | 23.28 Million USD | 8.09% |
| 2021 Q2 | 24.52 Million USD | 5.34% |
| 2021 Q3 | 26.59 Million USD | 8.45% |
| 2021 Q4 | 8.37 Million USD | -68.53% |
| 2020 Q1 | 36.02 Million USD | 18.82% |
| 2020 FY | 21.54 Million USD | -28.96% |
| 2020 Q2 | 21.5 Million USD | -40.3% |
| 2020 Q4 | 21.54 Million USD | 1.0% |
| 2020 Q3 | 21.32 Million USD | -0.84% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | 30.31 Million USD | 0.0% |
| 2019 FY | 30.31 Million USD | 50.8% |
| 2018 FY | 20.1 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Accuray Incorporated | 164.4 Million USD | 98.754% |
| Align Technology, Inc. | 96.96 Million USD | 97.887% |
| Elevance Health Inc. | 23.24 Billion USD | 99.991% |
| AxoGen, Inc. | 46.6 Million USD | 95.603% |
| Boston Scientific Corporation | 8.56 Billion USD | 99.976% |
| CVS Health Corporation | 74.67 Billion USD | 99.997% |
| Cardinal Health, Inc. | 4.58 Billion USD | 99.955% |
| Centene Corporation | 17.69 Billion USD | 99.988% |
| DaVita Inc. | 8.05 Billion USD | 99.975% |
| HCA Healthcare, Inc. | 36.62 Billion USD | 99.994% |
| Hologic, Inc. | 2.49 Billion USD | 99.918% |
| Humana Inc. | 10.21 Billion USD | 99.98% |
| IDEXX Laboratories, Inc. | 622.88 Million USD | 99.671% |
| Laboratory Corporation of America Holdings | 4.05 Billion USD | 99.949% |
| Masimo Corporation | 871.7 Million USD | 99.765% |
| McKesson Corporation | 5.45 Billion USD | 99.962% |
| Patterson Companies, Inc. | 328.91 Million USD | 99.377% |
| Quest Diagnostics Incorporated | 4.41 Billion USD | 99.954% |
| ResMed Inc. | 697.31 Million USD | 99.706% |
| Henry Schein, Inc. | 1.93 Billion USD | 99.894% |
| Teladoc Health, Inc. | 1.58 Billion USD | 99.87% |
| Universal Health Services, Inc. | 4.71 Billion USD | 99.957% |
| Veeva Systems Inc. | 46.44 Million USD | 95.588% |
| Baxter International Inc. | 11.06 Billion USD | 99.981% |
| Becton, Dickinson and Company | 14.73 Billion USD | 99.986% |
| Intuitive Surgical, Inc. | -82.1 Million USD | 102.496% |
| Danaher Corporation | 17.66 Billion USD | 99.988% |
| Stryker Corporation | 10.9 Billion USD | 99.981% |
| Medtronic plc | 23.87 Billion USD | 99.991% |